×
Kintara Therapeutics EBITDA 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Kintara Therapeutics ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Kintara Therapeutics EBITDA 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Kintara Therapeutics ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.2B
Vertex Pharmaceuticals (VRTX)
$123.4B
Gilead Sciences (GILD)
$107.4B
Regeneron Pharmaceuticals (REGN)
$106.8B
Bristol Myers Squibb (BMY)
$105.7B
CSL (CSLLY)
$97.7B
GSK (GSK)
$79.1B
Alnylam Pharmaceuticals (ALNY)
$37.5B
Argenex SE (ARGX)
$33.5B
Biogen (BIIB)
$26.9B
BioNTech SE (BNTX)
$26.5B
Illumina (ILMN)
$23.1B
BeiGene (BGNE)
$21.4B
Moderna (MRNA)
$20.7B
Genmab (GMAB)
$15.1B
BioMarin Pharmaceutical (BMRN)
$13.3B
Vaxcyte (PCVX)
$12.9B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.4B
Sarepta Therapeutics (SRPT)
$12.1B
Bio-Techne Corp (TECH)
$11.2B
QIAGEN (QGEN)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8.4B
Exelixis (EXEL)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Revolution Medicines (RVMD)
$8B
Legend Biotech (LEGN)
$7.9B